This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
Development of low-cost serological immunoassay to detect antiviral antibodies to Sars-Cov-2 Spike protein (preprint)
medrxiv; 2021.
Preprint
in English
| medRxiv | ID: ppzbmed-10.1101.2021.06.07.21258114
ABSTRACT
Seroconversion to Sars-cov-2 has been widely studied to evaluate infection spreading for epidemiological purpose, or even in studies of protective immunity in convalescent or vaccinated individuals. The viral particle has an envelope harboring the SPIKE glycoprotein, which can be used as an antigen for assay development, to detect antiviral antibodies to Sars-CoV-2. Since several vaccines encode a SPIKE subunit, the full length spike-based immunoassay should be a universal tool to evaluate seroconversion. In this manuscript, we propose a low-cost assay that can be used to detect antiviral IgG to Sars-Cov-2 in human serum.
Full text:
Available
Collection:
Preprints
Database:
medRxiv
Language:
English
Year:
2021
Document Type:
Preprint
Similar
MEDLINE
...
LILACS
LIS